Latest Content

Concussion recovery in teen athletes often masks anxiety or depression; learn warning signs, screening tips, and safer return-to-play steps.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

New BEST teletraining helps people after TBI name emotions, reduce anxiety and anger, and boost resilience—early trials show promise.

Placebo and nocebo effects shape psychiatric care—how expectations and framing boost medication benefit and reduce side effects.

Don't miss out on these CME articles! Test your knowledge here.

Review centanafadine ahead of the upcoming FDA decision on July 24.

ASCP updates spotlight ketamine safety guardrails, at‑home agitation therapy, psilocybin phase 3 momentum, and biomarker-driven precision psychiatry.

Top 2026 psychiatry conference takeaways: mixed-feature bipolar care, GLP-1 addiction trials, schizophrenia adherence, TD gaps, AI prodrome screening.

SIRS highlights new schizophrenia advances: LB-102 shows promise, Cobenfy switching stays stable, and tazbentetol targets synaptic regeneration.

How to recognize racial trauma, sharpen diagnosis, and apply “Cost of Capable” and “weathering” to build trust and assess suicide risk.

Should EDs use AI to spot suicide risk? Explore evidence, bias concerns, false positives, and what accreditation mandates could mean for care.

Meta-analysis ranks add-on atypical antipsychotics for MDD, comparing symptom response and dropout risks to guide smarter next-step treatment.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.